Safety of intravitreal panitumumab combined with intravitreal ranibizumab in rabbits.

ABSTRACT:

Purpose

To examine the safety of intravitreally applied epidermal growth factor (EGF) receptor antibody panitumumab combined with intravitreally injected vascular endothelial growth factor (VEGF) antibody ranibizumab in rabbits.

Methods

The experimental study included 8 male rabbits (age: 2-3 months; weight: 2.5-2.6 kg). The right eyes received three intravitreal injections of panitumumab (1 mg in 0.10 mL) combined with intravitreal injections of ranibizumab (0.5 mg in 0.05 mL) in intervals of 4 weeks, while the left eyes received three double intravitreal injections of Ringer´s solution (0.10 mL and 0.05mL). At baseline, at the time points of the re-injections, and at 2 weeks and at 6 weeks after the last injection, the animals were examined by fundus photography and optica

SUBMITTER: Bikbov MM 

PROVIDER: S-EPMC12707628 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature